• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transplantation . COVID-19 in Lung Transplant Recipients

tetano

Editor, Senior Moderator
Transplantation


. 2020 Oct 30.
doi: 10.1097/TP.0000000000003508. Online ahead of print.
COVID-19 in Lung Transplant Recipients


Jonathan Messika[SUP] 1 2 3 [/SUP], Philippine Eloy[SUP] 4 5 [/SUP], Antoine Roux[SUP] 3 6 7 [/SUP], Sandrine Hirschi[SUP] 8 [/SUP], Ana Nieves[SUP] 9 [/SUP], J?r?me Le Pavec[SUP] 10 11 12 [/SUP], Agathe S?n?chal[SUP] 13 [/SUP], Christel Saint Raymond[SUP] 14 [/SUP], Nicolas Carlier[SUP] 15 [/SUP], Xavier Demant[SUP] 16 [/SUP], Aur?lie Le Borgne[SUP] 17 [/SUP], Adrien Tissot[SUP] 18 [/SUP], Marie-Pierre Debray[SUP] 19 [/SUP], Laurence Beaumont[SUP] 6 [/SUP], Benjamin Renaud-Picard[SUP] 8 [/SUP], Martine Reynaud-Gaubert[SUP] 9 [/SUP], Jean-Fran?ois Mornex[SUP] 13 20 [/SUP], Lo?c Falque[SUP] 14 [/SUP], V?ronique Boussaud[SUP] 15 [/SUP], Jacques Jougon[SUP] 16 [/SUP], Sacha Mussot[SUP] 10 11 12 [/SUP], Herv? Mal[SUP] 1 2 [/SUP], French Group of Lung Transplantation.



Affiliations

Abstract

Background: A concern about the susceptibility of immunocompromised patients to the worldwide pandemic of coronavirus disease 2019 (COVID-19) has been raised. We aimed at describing COVID-19 infections in the French cohort of lung transplant (LT) patients.
Methods: Multicenter nationwide cohort study of all LT recipients with COVID-19 diagnosed from March 1 to May 19, 2020. Recipient main characteristics and their management were retrieved. Hospitalization characteristics, occurrence of complications and survival were analyzed.
Results: Thirty-five LT patients with a COVID-19 infection were included. Median age was 50.4 [40.6-62.9] years, 16 (45.7%) were female, and 80% were double-LT recipients. Infection was community-acquired in 25 (71.4%). Thirty-one (88.6%) required hospitalization, including 13 (41.9%) in the intensive care unit. The main symptoms of COVID-19 were fever, cough, and diarrhea, present in 71.4%, 54.3%, and 31.4% of cases, respectively. Extension of pneumonia on chest CT was moderate to severe in 51.4% of cases. Among the 13 critically ill patients, 7 (53.9%) received invasive mechanical ventilation. Thrombotic events occurred in 4 patients. Overall survival rate was 85.7% after a median follow-up of 50 days [41.0-56.5]. Four of 5 nonsurvivors had had bronchial complications or intensification of immunosuppression in the previous weeks. On univariate analysis, overweight was significantly associated with risk of death (odds ratio 16.0 [95% confidence interval1.5-170.6], p=0.02).
Conclusion: For the 35 LT recipients with COVID-19, the presentation was severe, requiring hospitalization in most cases, with a survival rate of 85.7%.
 
Back
Top Bottom